To determine the effect of transfemoral aortic valve implantation (TF-TAVI) on plasma BNP levels and to evaluate their predictive value for 30-day and one-year survival. Methods: Baseline BNP, peak BNP within 48 hours after TAVI and predischarge BNP were obtained in 104 patients who underwent TF-TAVI with complete one-year follow-up. Results: BNP was elevated at baseline (298.2, IQR 145.8, 661.6 pg/ml) and showed an acute increase after TF-TAVI (508.9, IQR 253.3, 868.6 pg/ml) followed by regression towards baseline levels prior to discharge (327.2, IQR 159.2, 634.6 pg/ml), pϽ 0.001. Acute BNP increase (⌬BNPpeak-baseline) is significantly higher in 30 days nonsurvivors (277.1 IQR 252.1, 810 pg/ml) than in survivors (132.8 IQR Ϫ10.1, 301 pg/ml), pϭ 0.028, and is found to be independent predictor of 30 days survival. Kaplan-Meier (KM) survival analysis showed a reduced 30 days survival in patients with a ⌬BNPpeak-baseline Ն 248.9 pg/ml, pϭ 0.002. For 1-year survival, predischarge BNP level (250.8, IQR 152.9, 621.8 pg/ml in survivors vs. 591, IQR 354.5, 788 pg/ml in non survivors, pϭ 0.003) and ⌬BNPdischarge-baseline(Ϫ211.8 IQR Ϫ521.5, Ϫ91.1 pg/ml in survivors vs. 108.4 IQR 12.2, 272.6 pg/ml in non survivors, pϭ0.002) are independent predictors. KM analysis showed that 1-year survival is significantly lower in patients with a predischarge BNP Ն327.2 and a ⌬BNPdischarge-baseline Ն Ϫ38.3 than in those not fulfilling both criteria, pϽ 0.001. Conclusions: BNP values are elevated in patients with severe, symptomatic aortic stenosis presenting for TF-TAVI. They further increase acutely after procedure and regress to baseline levels, usually prior to hospital-discharge. Acute, postprocedural BNP increase is an independent predictor of reduced 30 days survival, while reduced 1-year survival is predicted by higher predischarge BNP levels and failure of BNP to decline at discharge below baseline BNP level.
Background: Transcatheter aortic valve implantation (TAVI) is an accepted alternative in high-risk or inoperable patients with severe, symptomatic aortic stenosis. The trans-femoral (TF) approach is most widely used however is limited in those with peripheral vascular disease. The trans-apical (TA) and trans-axillary (TAx) approaches have been described for such patients with limited data on outcomes. This study reports our single center experience with both approaches and compares patient outcomes. Methods: A retrospective study of patients undergoing TAVI from January 2010 to December 2011. Procedural and clinical outcomes were defined according to the VARC definitions. Results: During the study period, 126 patients underwent TAVI at our hospital; 70 (55%) patients were done by TF, 41 (33%) by TA and 15 (12%) by the TAx. Indications for TAx or TA approach for TAVI in our institution were as follows: PVD in 34 patients (61%), suboptimal size of femoral arteries (arterial diameter Ͻϭ6 mm) in 23 (41%), AAA in 14 (25%), morbid obesity in 8 (14%). Procedural success, defined as implantation of the device with a reduction in aortic valve gradient and without the need for conversion to open heart surgery, was 93% (14/15) in TAx and 88% (36/41) in TA (pϭ1.00). In TAx group, two patients required retrieval of the devices and subsequent successful implantation of another valve with the same approach. Valve embolization occurred in three TA cases requiring conversion to conventional AVR. Conclusions: In this single center series the trans-axillary approach was associated with a trend towards higher procedural success, lower all-cause mortality and fewer bleeding complications than the trans-apical approach in patients with severe aortic stenosis. Larger randomized controlled trials will be required to determine the true superiority of one access site over the other. Background: Balloon valvuloplasty (BV) before transcatheter aortic implantation of the prosthesis has been considered a mandatory step before valve implantation. However, BV has been associated with complications such as atrioventricular block, aortic insufficiency and stroke. We report 10 patients with severe aortic stenosis in whom direct transfemoral implantation of the SAPIEN XT was performed. Methods: From November 2011 to April 2012, 10 patients (33% of patients treated with Edwards SAPIEN XT in that period were selected that met the following criteria: moderate calcification, homogeneous distribution of calcium, symmetrical opening of the valve and some degree of aortic insufficiency. The valve positioning was guided by TEE in all cases. Results: All patients had symptomatic aortic stenosis of a native valve and high risk surgical; echocardiographic characteristics were: aortic annulus diameter ranged from 17 to 24 mm (determined by TEE). Six patients had the valve midly calcified, in four patients the degree of calcification was moderate. All patients had symmetric opening of the stenotic aortic valve. Mild aortic regurgitation was present in seven patients, moderate in two and trivial in one. The native valve was crossed and the prosthetic aortic valve was properly positioned in all cases and implanted in the correct position in all cases. No patient underwent post-dilatation and only 1 patient had a mild periprosthetic regurgitation. There were no adverse events (death, need for pacemaker, myocardial infarction or stroke). At 30 days postprocedure all patients had significant clinical improvement. Conclusions: Direct implantation of Edwards SAPIEN XT without prior balloon valvuloplasty in selected cases is feasible and safe. The number of patients in whom this technique is applicable and their impact on reducing complications has to be determined. 
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